- Home
- DXCM
DXCM
DexCom Inc.
as 04-18-2025 1:35pm EST
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 27.7B | IPO Year: | 2005 |
| Target Price: | $99.00 | AVG Volume (30 days): | 4.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.42 | EPS Growth: | 9.35 |
| 52 Week Low/High: | $57.52 - $139.24 | Next Earning Date: | 05-01-2025 |
| Revenue: | $4,033,000,000 | Revenue Growth: | 11.34% |
| Revenue Growth (this year): | 16.39% | Revenue Growth (next year): | 15.64% |
Stock Insider Trading Activity of DexCom Inc. (DXCM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heller Bridgette P | DXCM | Director | Mar 17 '25 | Sell | $70.33 | 352 | $24,756.16 | 22,997 | |
| Brown Michael Jon | DXCM | EVP, Chief Legal Officer | Mar 12 '25 | Sell | $70.38 | 13,000 | $914,941.30 | 105,602 | |
| Sylvain Jereme M | DXCM | EVP, Chief Financal Officer | Mar 12 '25 | Sell | $70.38 | 12,001 | $844,631.58 | 123,481 | |
| SAYER KEVIN R | DXCM | Chairman, CEO & President | Mar 12 '25 | Sell | $70.38 | 32,498 | $2,287,212.49 | 372,029 | |
| Leach Jacob Steven | DXCM | EVP, Chief Operating Officer | Mar 12 '25 | Sell | $70.38 | 14,076 | $990,670.29 | 313,497 | |
| Stern Sadie | DXCM | EVP, Chief HR Officer | Mar 12 '25 | Sell | $70.38 | 11,176 | $786,568.00 | 115,805 | |
| Sylvain Jereme M | DXCM | EVP, Chief Financal Officer | Mar 8 '25 | Sell | $73.99 | 7,000 | $516,830.28 | 123,481 | |
| Sylvain Jereme M | DXCM | EVP, Chief Financal Officer | Jan 28 '25 | Sell | $86.91 | 2,090 | $181,650.47 | 123,481 | |
| SAYER KEVIN R | DXCM | Chairman, CEO & President | Jan 28 '25 | Sell | $86.91 | 33,359 | $2,899,367.46 | 372,029 | |
| Dolan Matthew Vincent | DXCM | EVP, Strategy & Corporate Dev | Jan 28 '25 | Sell | $86.91 | 1,183 | $102,819.74 | 42,044 |
Latest DexCom Inc. News
DXCM Breaking Stock News: Dive into DXCM Ticker-Specific Updates for Smart Investing
Simply Wall St.
20 hours ago
3 Top Value Stocks Estimated To Be Up To 46.8% Below Intrinsic Value
Simply Wall St.
3 days ago
DexCom (NasdaqGS:DXCM) Gains FDA Clearance For Dexcom G7 System
Motley Fool
3 days ago
Tariffs, Trump, and Turmoil
Argus Research
3 days ago
DXCM: Raising target price to $73.00
Argus Research
3 days ago
DXCM: Raising target price to $36.00
MT Newswires
4 days ago
RBC Cuts Price Target on DexCom to $100 From $115, Keeps Outperform Rating
Zacks
8 days ago
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance
Morningstar Research
8 days ago
Analyst Report: DexCom, Inc.
Compare DXCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DXCM DexCom Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.